H.C. Wainwright lifts Caribou Biosciences target to $11 on pipeline confidence

H.C. Wainwright analyst Robert Burns has raised his price target for Caribou Biosciences (NASDAQ: CRBU) to $11 from $9, maintaining a Buy rating on the stock. The revision, issued on May 11, follows the release of the company’s first-quarter results and signals growing confidence in its development pipeline and clinical progress.

The adjustment comes as Caribou Biosciences, a clinical-stage biopharmaceutical company headquartered in Berkeley, California, continues to advance its next-generation, off-the-shelf CRISPR-edited cell therapies. The firm, which completed its initial public offering in 2021, focuses on treating cancer and autoimmune diseases.

A key driver of the renewed investor interest is the recent regulatory recognition of the company’s lead asset. On March 31, the U.S. Food and Drug Administration granted Regenerative Medicine Advanced Therapy (RMAT) designation to CB-011 for the treatment of relapsed or refractory multiple myeloma.

CB-011 is an allogeneic anti-BCMA CAR-T cell therapy currently being evaluated in the ongoing Phase 1 CaMMamour clinical trial. The RMAT designation is designed to expedite the development and review of promising regenerative medicine therapies, potentially accelerating the programme’s path toward commercialisation.

At the time of the update, Caribou Biosciences shares were trading at $2.36. The analyst noted that the revised target reflects the potential value investors could realise if the company continues to execute on its strategic and operational objectives.